FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Rapid communications in mass spectrometry : RCM2024; 38(23); e9916; doi: 10.1002/rcm.9916

Equine metabolic investigation of the phosphodiesterase-4 inhibitor ibudilast as a potential performance enhancer.

Abstract: Phosphodiesterase 4 (PDE4) inhibitors are a newer class of drugs that induce bronchodilation and have anti-inflammatory effects, making them susceptible to misuse as performance enhancers in competitive sports. Methods: This study explores the metabolic conversion of PDE4 inhibitor ibudilast in thoroughbred horses after oral administration and in vitro using equine liver microsomes and Cunninghamella elegans. A liquid chromatography-high resolution mass spectrometry method was used to postulate the plausible structures of the detected metabolites. Results: A total of 20 in vivo metabolites were identified under experimental conditions, including 12 Phase I and 8 Phase II conjugated metabolites. Phase I metabolites were predominantly formed through hydroxylation (mono-, di-, and tri-hydroxylation). Demethylated metabolites were also identified during this investigation. Additionally, the research detected Phase II metabolites conjugated with glucuronic and sulfonic acids. Conclusions: The data presented here can assist in detecting the PDE4 inhibitor ibudilast and uncover its illicit use in competitive sports.
© 2024 John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2024-09-23 PubMed ID: 39307998DOI: 10.1002/rcm.9916Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study investigates how a drug known as ibudilast, which falls under the class of phosphodiesterase 4 (PDE4) inhibitors, is metabolized in thoroughbred horses. The findings of this study can potentially help in detecting illicit use of this drug in competitive sports.

Research Methods

  • The researchers focused on the metabolic conversion of ibudilast, a PDE4 inhibitor, in thoroughbred horses. They used various methods including oral administration to the horses and in vitro testing using horse liver microsomes and an organism known as Cunninghamella elegans.
  • A method called liquid chromatography high-resolution mass spectrometry was implemented. This method helped the researchers to hypothesize the potential structures of the detected metabolites of the drug.

Research Findings

  • Based on the analysis, a total of 20 unique metabolites were generated under the experimental conditions. Among these 20 compounds, there were 12 Phase I and 8 Phase II metabolites.
  • The Phase I metabolites were mainly created through hydroxylation, which includes mono-hydroxylation, di-hydroxylation, and tri-hydroxylation.
  • The experiment also identified demethylated metabolites, which involve the subtraction of a methyl group.
  • In addition to these, Phase II metabolites were identified, which were specifically conjugated with glucuronic and sulfonic acids. Conjugation is a phase of drug metabolism where the body makes the drug or its metabolites more soluble in water for easier elimination.

Research Conclusions

  • The researchers concluded that the data obtained from this study could potentially aid in detecting ibudilast, a PDE4 inhibitor, in sport horse doping events.
  • Identifying the metabolic products of ibudilast not only helps detect its presence but also provides additional insights into how the drug is processed in horse bodies, which could be vital in situations of misusage in competitive sports.

Cite This Article

APA
Philip M, Kal AKK, Subhahar MB, Karatt TK, Graiban FM, Ajeebsanu MM, Joseph M, Jose SV. (2024). Equine metabolic investigation of the phosphodiesterase-4 inhibitor ibudilast as a potential performance enhancer. Rapid Commun Mass Spectrom, 38(23), e9916. https://doi.org/10.1002/rcm.9916

Publication

Rapid communications in mass spectrometry : RCM
ISSN: 1097-0231
NlmUniqueID: 8802365
Country: England
Language: English
Volume: 38
Issue: 23
Pages: e9916

Researcher Affiliations

Philip, Moses
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Kal, Abdul Khader Karakka
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Subhahar, Michael Benedict
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Karatt, Tajudheen K
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Graiban, Fatma Mohammed
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Ajeebsanu, Meleparappil Muhammed
  • Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Joseph, Marina
  • Department of Bacteriology, Diagnostic Section, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.
Jose, Shantymol V
  • Department of Bacteriology, Diagnostic Section, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.

MeSH Terms

  • Animals
  • Horses
  • Phosphodiesterase 4 Inhibitors / metabolism
  • Phosphodiesterase 4 Inhibitors / chemistry
  • Phosphodiesterase 4 Inhibitors / pharmacology
  • Pyridines / metabolism
  • Pyridines / chemistry
  • Pyridines / pharmacology
  • Pyridines / analysis
  • Microsomes, Liver / metabolism
  • Microsomes, Liver / drug effects
  • Performance-Enhancing Substances / metabolism
  • Performance-Enhancing Substances / chemistry
  • Performance-Enhancing Substances / pharmacology
  • Doping in Sports
  • Indolizines
  • Pyrazoles

References

This article includes 28 references
  1. Weiss B. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase.. Adv Cyclic Nucleotide Res 1975;5:195‐211.
  2. Gamble E, Grootendorst DC, Brightling CE. Anti‐inflammatory effects of the phosphodiesterase‐4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.. Am J Respir Crit Care Med 2003;168(8):976‐982.
    doi: 10.1164/rccm.200212-1490ocgoogle scholar: lookup
  3. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.. Pharmacol Ther 2006;109(3):366‐398.
    doi: 10.1016/j.pharmthera.2005.07.003google scholar: lookup
  4. Bateman ED, Rabe KF, Calverley PM. Roflumilast with long‐acting β2‐agonists for COPD: influence of exacerbation history.. Eur Respir J 2011;38(3):553‐560.
    doi: 10.1183/09031936.00178710google scholar: lookup
  5. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.. Cochrane Database Syst Rev 2017;9(9):1‐147.
    doi: 10.1002/14651858.cd002309google scholar: lookup
  6. Facchinetti F, Civelli M, Singh D, Papi A, Emirova A, Govoni M. Tanimilast, a novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.. Front Pharmacol 2021;12:740803.
    doi: 10.3389/fphar.2021.740803google scholar: lookup
  7. Boswell‐Smith V, Spina D, Page CP. Phosphodiesterase inhibitors.. Br J Pharmacol 2006;147(S1):S252‐S257.
    doi: 10.1038/sj.bjp.0706495google scholar: lookup
  8. Kawasaki A, Hoshino K, Osaki R, Mizushima Y, Yano S. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma.. Journal of Asthma 1992;29(4):245‐252.
    doi: 10.3109/02770909209048938google scholar: lookup
  9. Yamazaki T, Anraku T, Matsuzawa S. Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP‐independent relaxation of the intracranial vertebrobasilar artery.. Eur J Pharmacol 2011;650(2‐3):605‐611.
    doi: 10.1016/j.ejphar.2010.10.033google scholar: lookup
  10. Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M. Ibudilast: a non‐selective PDE inhibitor with multiple actions on blood cells and the vascular wall.. Cardiovasc Drug Rev 2001;19(3):215‐225.
    doi: 10.1111/j.1527-3466.2001.tb00066.xgoogle scholar: lookup
  11. Huang Z, Liu S, Zhang L. Preferential inhibition of human phosphodiesterase 4 by ibudilast.. Life Sci 2006;78(23):2663‐2668.
    doi: 10.1016/j.lfs.2005.10.026google scholar: lookup
  12. Suzumura A, Ito A, Yoshikawa M, Sawada M. Ibudilast suppresses TNF alpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS.. Brain Res 1999;837(1–2):203‐212.
    doi: 10.1016/s0006-8993(99)01666-2google scholar: lookup
  13. Rolan P, Hutchinson M, Johnson K. Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.. Expert Opin Pharmacother 2009;10(17):2897‐2904.
    doi: 10.1517/14656560903426189google scholar: lookup
  14. Kagitani‐Shimono K, Mohri I, Fujitani Y. Anti‐inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.. J Neuroinflammation 2005;2(1):10.
    doi: 10.1186/1742-2094-2-10google scholar: lookup
  15. Goodman AD, Gyang T, Smith AD. Ibudilast for the treatment of multiple sclerosis.. Expert Opin Investig Drugs 2016;25(10):1231‐1237.
    doi: 10.1080/13543784.2016.1221924google scholar: lookup
  16. Schwenkgrub J, Zaremba M, Mirowska‐Guzel D, Kurkowska‐Jastrzębska I. Ibudilast: a non‐selective phosphodiesterase inhibitor in brain disorders.. Postepy Hig Med Dosw (Online) 2017;71(0):137‐148.
    doi: 10.5604/01.3001.0010.3798google scholar: lookup
  17. Oliveros G, Wallace CH, Chaudry O. Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.. Brain 2023;146(3):898‐911.
    doi: 10.1093/brain/awac136google scholar: lookup
  18. Naismith RT, Bermel RA, Coffey CS. Effects of ibudilast on MRI measures in the phase 2 SPRINT‐MS study.. Neurology 2021;96(4):e491‐e500.
    doi: 10.1212/wnl.0000000000011314google scholar: lookup
  19. Zhang W, Matsukane R, Egashira N. Neuroprotective effects of ibudilast against tacrolimus induced neurotoxicity.. Toxicol Appl Pharmacol 2022;449:116112.
    doi: 10.1016/j.taap.2022.116112google scholar: lookup
  20. Angelopoulou E, Pyrgelis ES, Piperi C. Emerging potential of the phosphodiesterase (PDE) inhibitor ibudilast for neurodegenerative diseases: an update on preclinical and clinical evidence.. Molecules 2022;27(23):8448.
    doi: 10.3390/molecules27238448google scholar: lookup
  21. Meredith LR, Green R, Grodin EN, Chorpita M, Miotto K, Ray LA. Ibudilast moderates the effect of mood on alcohol craving during stress exposure.. Exp Clin Psychopharmacol 2022;30(5):620‐631.
    doi: 10.1037/pha0000458google scholar: lookup
  22. Karatt TK, Sathiq MA, Laya S. In‐depth metabolic study of nonsteroidal selective androgen receptor modulator GSK2881078 in thoroughbred horses and horse liver microsomes for doping control.. Drug Test Anal 2023;15(7):757‐768.
    doi: 10.1002/dta.3469google scholar: lookup
  23. Philip M, Abdul Khader KK, Subhahar MB, Karatt TK, Mathew B, Koshy SA. Characterization of growth hormone secretagogue small molecule ibutamoren (MK‐0677) and its possible metabolites in thoroughbred horses for doping control.. Rapid Commun Mass Spectrom 2022;36(18):e9337.
    doi: 10.1002/rcm.9337google scholar: lookup
  24. Philip M, Abdul Khader KK, Subhahar MB, Perwad Z, Karatt TK. Characterization of equine liver microsome‐generated metabolites of growth hormone secretagogue small molecule ibutamoren.. Rapid Commun Mass Spectrom 2021;35(23):e9201.
    doi: 10.1002/rcm.9201google scholar: lookup
  25. Muhammed Ajeebsanu M, Subhahar MB, Abdul Khader KK. Comprehensive metabolic investigation of dopamine reuptake inhibitor HDMP‐28 in equine liver microsomes and Cunninghamella elegans for doping control.. Drug Test Anal 2024;1‐13.
    doi: 10.1002/dta.3642google scholar: lookup
  26. Karatt TK, Sathiq MA, Laya S, Philip M, Abdul Khader KK, Subhahar MB. Investigation of in vitro generated metabolites of GLPG0492 using equine liver microsomes for doping control.. Drug Test Anal 2023;15(6):605‐628.
    doi: 10.1002/dta.3453google scholar: lookup
  27. Philip M, Abdul Khader KK, Subhahar MB, Karatt TK, Mathew B, Perwad Z. In vitro studies of hypoxia inducible factor‐prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.. Drug Test Anal 2022;14(2):317‐348.
    doi: 10.1002/dta.3188google scholar: lookup
  28. Watanabe S, Iwai T, Matsushita R. Comparison between human liver microsomes and the fungus Cunninghamella elegans for biotransformation of the synthetic cannabinoid JWH‐424 having a bromo‐naphthyl moiety analysed by high‐resolution mass spectrometry.. Forensic Toxicol 2022;40(2):278‐288.
    doi: 10.1007/s11419-022-00612-2google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.